Evidence map›Paper›PMID 42785814›Full record

ArticleLupus science & medicine2026

National trends in hospitalisation, in-hospital mortality and resource use for SLE in Spain from 2016 to 2022.

Luis Arribas-Pérez, Francisco Josué Cordero-Pérez, David Puertas-Miranda, Erik Gabriel Díaz-Avila, Leticia Salcedo-Martín, Hugo Guillermo Ternavasio-de la Vega, Jorge L Torres-Triana, Miguel Marcos, Antonio-J Chamorro

Abstract read
In one paragraph

Article in Lupus science & medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Luis Arribas-PérezDepartment of Internal Medicine, Complejo Asistencial de Zamora, Zamora, Spain.ORCID 0009-0005-8833-3268
Francisco Josué Cordero-PérezDepartment of Internal Medicine, Complejo Asistencial de Zamora, Zamora, Spain.
David Puertas-MirandaInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Erik Gabriel Díaz-AvilaDepartment of Medicine. Faculty of Medicine, Universidad de Salamanca, Salamanca, Spain.ORCID 0000-0002-2590-9734
Leticia Salcedo-MartínInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Hugo Guillermo Ternavasio-de la VegaDepartment of Internal Medicine, Complejo Asistencial de Zamora, Zamora, Spain.
Jorge L Torres-TrianaDepartment of Internal Medicine, Complejo Asistencial de Zamora, Zamora, Spain.ORCID 0000-0001-6853-9115
Miguel MarcosInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.
Antonio-J ChamorroInstitute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain ajchamorro@usal.es.ORCID 0000-0002-2345-2873

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveSLE is a complex autoimmune disease that causes significant health issues. In this study, SLE-related healthcare episodes, in-hospital mortality and resource use in Spain from 2016 to 2022 were assessed.

methodsIn this retrospective, nationwide, repeated cross-sectional study, International Classification of Diseases, 10th Revision, data from Spain's National Hospital Discharge Registry were used to identify healthcare episodes with SLE (or its subtypes) coded as the principal diagnosis. Temporal trends were analysed and group comparisons were made using χ², Fisher's exact test, Student's t test and Mantel-Haenszel trend test.

resultsA total of 24 151 SLE episodes were identified, with the majority occurring in women (86.9%) and individuals aged 15-65 years (88.2%). SLE episodes increased from 3002 (6.5/100 000 population) in 2016 to 4226 (8.8/100 000 population) in 2022 (p<0.001). Lupus nephritis episodes rose from 525 (1.13/100 000 population) to 956 (2.0/100 000 population; p<0.001). Relative to all other hospitalisation episodes, SLE episodes had longer hospital stays (8.7 vs 7.1 days; p<0.001) and intensive care unit (ICU) stays (8.4 vs 4.9 days; p=0.031). In-hospital mortality was low and stable. In unadjusted comparisons, mortality was lower among SLE episodes than among other hospitalisation episodes (0.3% vs 1.2%; p<0.001). A larger proportion of in-hospital deaths during SLE episodes than during all other hospitalisation episodes occurred in individuals aged 15-65 years (42.5% vs 15.1%; p<0.001). Although more deaths occurred in women, mortality was higher among men in unadjusted comparisons (0.7% vs 0.3%; p<0.001).

conclusionsSLE-related healthcare episodes increased in Spain from 2016 to 2022, but in-hospital mortality remained stable. SLE episodes involved longer hospital and ICU stays than other episodes. These results reflect healthcare utilisation patterns, not disease severity or patient outcomes.

Indexed as

HospitalizationHospital MortalityLupus Erythematosus, SystemicAdolescentAdultAgedCross-Sectional StudiesFemaleHumansLength of StayMaleMiddle AgedRetrospective StudiesSpainYoung AdultAutoimmune DiseasesEpidemiologyHealth services researchLupus Erythematosus, SystemicMortality

Identifiers

PMID42785814
PMCPMC13629960

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.